BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (British Journal of Cancer (2010) 103 (668675) Doi:10.1038/sj.bjc.6605736)

SJ Dawson; N Makretsov; FM Blows; KE Driver; E Provenzano; J Le Quesne; L Baglietto; G Severi; GG Giles; CA McLean; G Callagy; AR Green; I Ellis; K Gelmon; G Turashvili; S Leung; S Aparicio; D Huntsman; C Caldas; P Pharoah

Journal article

BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received (British Journal of Cancer (2010) 103 (668675) Doi:10.1038/sj.bjc.6605736)

SJ Dawson, N Makretsov, FM Blows, KE Driver, E Provenzano, J Le Quesne, L Baglietto, G Severi, GG Giles, CA McLean, G Callagy, AR Green, I Ellis, K Gelmon, G Turashvili, S Leung, S Aparicio, D Huntsman, C Caldas, P Pharoah

British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2010

DOI: 10.1038/sj.bjc.6605921

Abstract

Correction to: British Journal of Cancer (2010) 103: 668–675. doi:10.1038/sj.bjc.6605736 Upon publication of the above paper in Volume 103, Issue 5, the authors noticed an error in Table 1, wherein some of the totals in the final column were incorrect. The correct Table 1 is as shown here.